Abstract 5058
Background
Caregiving a cancer patient is a complex role that involves new responsibilities for which caregivers don’t feel ready to provide care. Caregivers who feel unprepared for giving care have physical, psychological and social problems. It is necessary to determine all the needs of caregivers.
Methods
This is cross-sectional descriptive study was carried out with 203 Turkish cancer family caregivers at the oncology wards of six hospital from January-March 2019. We defined a caregiver as one of the family members who give most assistance. Data were collected with “Preparedness Scale of the Family Care Inventory”. The scale consists of eight items, total score range is 0-32. Higher scores indicate that the caregiver feels more prepared for their role. Data were evaluated by independent groups t test, one-way analysis of variance test.
Results
The mean age of the caregivers was 46.8±13.8; most of them were female (64.5%); 68% of them felt constantly tired during the caregiving period; 55% had a decrease in social relations. Seventy one percent of the caregivers expressed that they wanted to know about the practices to protect their patients from infection; 64% of them wanted to know about what to do in case of emergency. Caregivers’ mean score from the scale was 27.0±6.0. Preparedness scores of those with high socioeconomic status are higher than those with low socioeconomic status (F = 4.047; p = 0.001). Less than one-year caregivers are more ready to provide care than caregivers for between one-five years; and between six-ten years caregivers are more ready to provide care than between one-five years (F = 6.464; p = 0.002).
Conclusions
Meeting caregiving needs is associated with high socioeconomic status. It is expected result that high socioeconomic status is related to preparedness for caregiving. Less than one-year caregivers encounter less problems. Nurses need to recognize that ’new’ cancer caregivers may be feeling difficulty when the problem is encountered. Caregivers with more experience duration develop the ability to solve care problems as the time to care for cancer patients increases. Nurses need to recognize that caregivers often are ’experienced’ caregivers may be feeling burnout and ignore their own health-related problems.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract